Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation

Introduction Opioid use disorder (OUD) is a debilitating and persistent disorder. The standard-of-care treatment is daily maintenance dosing of sublingual buprenorphine (BUP-SL) or oral methadone (MET). Monthly, extended-release, subcutaneous injectable buprenorphine (BUP-XR) has been developed to e...

Full description

Bibliographic Details
Main Authors: Eilish Gilvarry, Luke Mitcheson, Edward Day, John Marsden, Natalie Lowry, Fiona Cowden, Stacey Johnstone, Robbie Murray, Mike Kelleher
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/10/e067194.full

Internet

https://bmjopen.bmj.com/content/12/10/e067194.full

Similar Items